1,1-dimethylethyl 7-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2(1H)-isoquinolinecarboxylate | 253801-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1,1-dimethylethyl 7-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2(1H)-isoquinolinecarboxylate
• 英文别名: tert-butyl 7-(trifluoro-methanesulfonyl)oxy-3,4-dihydroisoquinoline-2(1H)-carboxylate；tert-Butyl 7-{[(trifluoromethyl)sulphonyl]oxy}-3,4-dihydro-2(1H)-isoquinolinecarboxylate；tert-butyl 7-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydroisoquinoline-2(1H)-carboxylate；tert-butyl 7-(trifluoromethylsulfonyloxy)-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 253801-21-7
• 化学式: C₁₅H₁₈F₃NO₅S
• 分子量: 381.373
• InChiKey: WVRZGRHQTHJOHC-UHFFFAOYSA-N

物化性质

• 沸点：
  430.9±45.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 7-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2(1H)-isoquinolinecarboxylate 在 盐酸 、 copper(l) iodide 、 四(三苯基膦)钯 、 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3)

  摘要：

  A series of benzothiophene methyl amines were examined in an effort to identify non-amidine chemotypes with reduced polypharmacology from existing leads with the goal of finding potent ASIC3 channel blockers to advance the therapeutic evaluation of ASIC3 inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.064
• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-7-醇 以 二氯甲烷 为溶剂， 生成 1,1-dimethylethyl 7-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2(1H)-isoquinolinecarboxylate
  参考文献：
  名称：

  Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3)

  摘要：

  A series of benzothiophene methyl amines were examined in an effort to identify non-amidine chemotypes with reduced polypharmacology from existing leads with the goal of finding potent ASIC3 channel blockers to advance the therapeutic evaluation of ASIC3 inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.064

文献信息

• Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure–activity relationships. Part 2
  作者：Takao Horiuchi、Motoko Nagata、Mayumi Kitagawa、Kouichi Akahane、Kouichi Uoto

  DOI：10.1016/j.bmc.2009.10.039

  日期：2009.12

  The design, synthesis and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitor are described. Focusing on the optimization of the heteroaryl moiety at the hydrazone with substituted phenyl groups, 4-[(methylamino)methyl]benzaldehyde (22) and 5-isoindolinecarbaldehyde (24) (6-tert-butylthieno[2,3-d]pyrimidin-4-yl)hydrazone derivatives have

  描述，设计和合成新型噻吩并[2,3 - d ]嘧啶-4-基类似物作为细胞周期蛋白依赖性激酶4（CDK4）抑制剂。重点研究the上带有取代苯基，4-[（（甲基氨基）甲基]苯甲醛（22）和5-异二氢吲哚甲醛（24）（6-叔丁基硫代[2,3- d ]嘧啶-已经鉴定出4-基）hydr衍生物。在本文中，讨论了我们合成化合物的效价，选择性和结构活性关系。
• METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：IGNAR DIANE MICHELE

  公开号：US20100113512A1

  公开（公告）日：2010-05-06

  A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

  使用含有新型阿片受体拮抗剂或反向激动剂的药物组合物治疗暴食症、厌食症、暴食症、过度药物或酒精使用或其他未明确指定的进食障碍的治疗方法。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：Cowan David John

  公开号：US20110124559A1

  公开（公告）日：2011-05-26

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物，它们是阿片受体的拮抗剂或逆向激动剂，含有它们的药物组合物，以及它们的制备方法。
• AMIDINE DERIVATIVE
  申请人：MATSUMOTO Kayo

  公开号：US20110172416A1

  公开（公告）日：2011-07-14

  Provision of a novel amidine derivative or a pharmaceutically acceptable salt thereof having an activated blood coagulation factor X-inhibitory activity. A compound represented by the formula (I) wherein each symbol is as defined above, or a pharmaceutically acceptable salt thereof.

  提供一种新型的氨基脲衍生物或其药学上可接受的盐，具有激活的血凝因子X抑制活性。化合物的结构式如下（I），其中每个符号如上所定义，或其药学上可接受的盐。
• Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
  申请人：GlaxoSmithKline LLC

  公开号：US20140323487A1

  公开（公告）日：2014-10-30

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物是阿片受体拮抗剂或反向激动剂，药物组合物包含它们，以及它们的制备方法。